Normal saline or dextrose

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Metastatic Castration-Resistant Prostate CancerOvarianfallopian tubeor primary peritoneal carcinoma.

Phase 3

A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)

CompletedCTIS2022-500785-10-00

Merck Sharp & Dohme LLCMetastatic Castration-Resistant Prostate Cancer

Start: 2019-08-23End: 2025-08-20Target: 420Updated: 2025-09-10

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96 / ENGOT-ov65).

Active, not recruitingCTIS2023-506177-35-00

Merck Sharp & Dohme LLCfallopian tube, or primary peritoneal carcinoma., Ovarian

Start: 2021-10-23Target: 209Updated: 2025-10-16